TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the U.S.

The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway, announced Cybin Inc. CYBN, which is sponsoring the research that will make heavy use ...

Recent advances in brain imaging techniques facilitate accurate, high-resolution observations of the brain and its functions. For example, functional near-infrared spectroscopy (fNIRS) is a widely ...

New feasibility study indicates that VR has the potential to drive physiological changes in the body and brain associated with pain relief LOS ANGELES, Feb. 8, 2024 /PRNewswire/ -- AppliedVR ®, a ...

Neural patterns predicted which participants classified as high or low performers based on attention networks during the game. LOS ANGELES--(BUSINESS WIRE)--Kernel, a leader in non-invasive ...